{{Drugbox
| IUPAC_name = (2-Amino-2-oxoethyl)[bis(4-fluorophenyl)methyl]sulfoniumolate
| image = CRL-40,940.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 90280-13-0
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 13271852

|  ChemSpiderID = 26386803

<!--Chemical data-->
| C=15 | H=13 | F=2 | N=1 | O=2 | S=1 
| molecular_weight = 309.33 g/mol
| melting_point = 
| smiles            = C1=CC(=CC=C1C(C2=CC=C(C=C2)F)S(=O)CC(=O)N)F
|  StdInChI = 1S/C15H13F2NO2S/c16-12-5-1-10(2-6-12)15(21(20)9-14(18)19)11-3-7-13(17)8-4-11/h1-8,15H,9H2,(H2,18,19)
|  StdInChIKey = YEAQNUMCWMRYMU-UHFFFAOYSA-N
}}

'''CRL-40,940''' (also known as '''flmodafinil''', '''bisfluoromodafinil''' and '''lauflumide''') is a selective dopaminergic reuptake inhibitor, and is the bisfluoro [[Structural analog|analog]] of the [[eugeroic]] [[modafinil]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.google.com/patents/CA1199916A1 | title=Patent CA 1199916 A1 - Benzhydrylsulfinylacetamide derivatives | author=Louis Lafon | date=28 January 1986 | accessdate=25 July 2015}}</ref><ref>{{cite journal | title=SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues |author1=Jianjing Cao |author2=Thomas E. Prisinzano |author3=Oluyomi M. Okunola |author4=Theresa Kopajtic |author5=Matthew Shook |author6=Jonathan L. Katz |author7=Amy Hauck Newman | journal=ACS Medicinal Chemistry Letters |date=January 2011  | volume=2 | issue=1 | pages=48â€“52 | doi=10.1021/ml1002025 | pmid=21344069 | pmc=3041981}}</ref><ref>{{cite web | url=https://www.google.com/patents/US20130295196 | title=Patent US 20130295196 A1 - Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof | date=7 November 2013 | accessdate=25 July 2015 | author=Eric Konofal}}</ref><ref>{{cite web | url=https://www.google.com/patents/US4489095 | title=Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids | date=18 December 1984 | accessdate=25 July 2015 | author=Louis Lafon}}</ref> Its inventors claim that it is more effective than modafinil and adrafinil in their indications with fewer side effects, and was patented in 2013.<ref>http://www.google.com/patents/US20130295196</ref> Phase I clinical trials have been underway since December 2015.<ref>http://nlspharma.com/science/pipeline/</ref><ref>http://adisinsight.springer.com/drugs/800043932</ref>

==See also==
* [[Adrafinil]]
* [[Armodafinil]]
* [[CRL-40,941]]
* [[Fluorenol]]
* [[Modafinil]]

==References==
{{Reflist|2}}

{{Stimulants}}
{{Dopaminergics}}

[[Category:Acetamides]]
[[Category:Designer drugs]]
[[Category:Dopamine reuptake inhibitors]]
[[Category:Drugs with unknown mechanisms of action]]
[[Category:Fluoroarenes]]
[[Category:Nootropics]]
[[Category:Stimulants]]
[[Category:Sulfoxides]]

{{nervous-system-drug-stub}}